Amarin ( (AMRN) ) just unveiled an announcement.
On March 12, 2025, Amarin announced a 1-for-20 reverse split of its American depositary shares (ADSs) to maintain its Nasdaq listing, effective around April 11, 2025. This move is expected to proportionally increase the trading price of its ADSs, although no assurance is given that the price will be 20 times higher post-split. In 2024, Amarin reported $62.3 million in fourth-quarter revenue, a 17% decrease from the previous year, primarily due to U.S. generic competition. Despite this, the company made significant progress in expanding its VASCEPA/VAZKEPA franchise globally, securing reimbursements in Italy and Austria, and advancing commercialization efforts in other markets.
More about Amarin
Amarin Corporation plc is a pharmaceutical company focused on the development and commercialization of therapeutics to improve cardiovascular health. Its primary product is VASCEPA/VAZKEPA (icosapent ethyl), which is used for cardiovascular risk reduction. The company has a strong presence in the U.S. market and is expanding its reach globally, including in Europe and other international markets.
YTD Price Performance: -9.62%
Average Trading Volume: 1,351,740
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $193.5M
For detailed information about AMRN stock, go to TipRanks’ Stock Analysis page.